VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

CONy 2022 | The future of oral-CGRP drugs in migraine prevention

Sait Ashina, MD, Harvard Medical School, Boston, MA, comments on what needs to be done to optimize oral-CGRP drugs in preventing migraines. He emphasizes the need for more long-term data in terms of how they are treating patients, as well as efficacy and safety data. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.

Disclosures

Dr Ashina is a consultant for Allergan/AbbVie, Amgen, Biohaven, Eli Lilly, Impel NeuroPharma, Novartis, Satsuma, Supernus, Theranica and Percept.